ASCO 2019 – Isatuximab plus pomalidomide and dexamethasone showed 40% reduction in the risk of disease progression for relapsed myeloma patients
ASCO 2019, CHICAGO – Pivotal Phase 3 ICARIA-MM trial results demonstrated that isatuximab added to pomalidomide and dexamethasone (isatuximab combination therapy) showed statistically significant improvements compared to pomalidomide and dexamethasone (pom-dex) alone in patients with relapsed/refractory multiple myeloma (RRMM).